Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

105.98USD
18 May 2018
Change (% chg)

$0.66 (+0.63%)
Prev Close
$105.32
Open
$105.27
Day's High
$106.78
Day's Low
$105.13
Volume
1,433,628
Avg. Vol
1,717,344
52-wk High
$125.84
52-wk Low
$64.80

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $167,130.09
Shares Outstanding(Mil.): 1,586.88
Dividend: 0.96
Yield (%): 3.62

Financials

  ABBV.N Industry Sector
P/E (TTM): 17.03 28.57 32.53
EPS (TTM): 6.22 -- --
ROI: 18.30 13.08 12.63
ROE: 233.05 14.80 14.50

BRIEF-AbbVie Inc Says On May 17, Entered Loan Credit Agreement To Borrow Up To $3 Bln

* ABBVIE INC - ON MAY 17, ENTERED TERM LOAN CREDIT AGREEMENT TO BORROW TERM LOANS ON AN UNSECURED BASIS OF UP TO $3 BILLION - SEC FILING Source http://bit.ly/2IuwcL8 Further company coverage:

18 May 2018

Goldman's Waldron says U.S. tax reform boosts shareholder activism

LOS ANGELES U.S. companies with more cash on their balance sheets thanks to tax reform are coming under greater scrutiny from activist investors, a top Goldman Sachs Group Inc investment banker said this week.

02 May 2018

REFILE-Goldman's Waldron says U.S. tax reform boosts shareholder activism

LOS ANGELES, May 2 U.S. companies with more cash on their balance sheets thanks to tax reform are coming under greater scrutiny from activist investors, a top Goldman Sachs Group Inc investment banker said this week.

02 May 2018

BRIEF-Abbvie Estimates Complete Blackout Could Begin As Soon As 4 P.M NY Time on May 23

* ABBVIE - ESTIMATE THAT COMPLETE BLACKOUT COULD BEGIN AS SOON AS 4 P.M., NEW YORK CITY TIME ON MAY 23, 2018 AND COULD EXTEND THROUGH JUNE 13, 2018 Further company coverage:

01 May 2018

BRIEF-Abbvie Submits Marketing Authorization Application To EMA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis

* ABBVIE SUBMITS MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR INVESTIGATIONAL TREATMENT RISANKIZUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS

01 May 2018

BRIEF-AbbVie Commences Self-Tender Offer For Up To $7.5 Bln Of Its Common Stock

* ABBVIE COMMENCES SELF-TENDER OFFER FOR UP TO $7.5 BILLION OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

01 May 2018

AbbVie's beat fueled by demand for Humira, Hep C drugs

AbbVie Inc reported a better-than-expected quarterly profit on Thursday, on higher sales of its rheumatoid arthritis treatment Humira and its Hepatitis C drugs, leading the company to raise its full-year earnings forecast.

26 Apr 2018

BRIEF-Abbvie Inc Reports Q1 GAAP Earnings Per Share Of $1.74

* QUARTERLY WORLDWIDE NET REVENUE $7.93 BILLION, UP 21.4 PERCENT ON GAAP BASIS

26 Apr 2018

AbbVie beats quarterly revenue estimates, raises earnings forecast

April 26 AbbVie Inc's first-quarter revenue beat analysts' estimates on Thursday on higher sales of its rheumatoid arthritis drug Humira and cancer treatment Imbruvica, while raising full-year earnings forecast.

26 Apr 2018

BRIEF-Abbvie's Upadacitinib Meets Primary And Key Efficacy Endpoints In Phase 2B/3 Rheumatoid Arthritis Study In Japanese Patients

* ABBVIE'S UPADACITINIB MEETS PRIMARY AND KEY EFFICACY ENDPOINTS IN PHASE 2B/3 RHEUMATOID ARTHRITIS STUDY IN JAPANESE PATIENTS

25 Apr 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.24 +0.39
Pfizer Inc. (PFE.N) $35.64 -0.07
Novartis AG (NOVN.S) CHF77.00 -0.64
Merck & Co., Inc. (MRK.N) $59.14 +0.07
Roche Holding Ltd. (ROG.S) CHF224.55 +0.55
Roche Holding Ltd. (RO.S) CHF229.20 +1.00
Abbott Laboratories (ABT.N) $61.71 +0.65
Eli Lilly And Co (LLY.N) $82.07 +0.41
Sanofi SA (SASY.PA) €66.44 +0.32

Earnings vs. Estimates